Publications by authors named "Marc Rudoltz"

Claim this Profile
P
Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients.
Vivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, Michael A Kiebish, Leonardo O Rodrigues, Marc S Rudoltz

Cancer Res Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
Filip Janku, Seung-Hoon Beom, Yong Wha Moon, Tae Won Kim, Young G Shin, Marc S Rudoltz

Invest New Drugs· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of Oxidative Phosphorylation with IM156 Attenuates Mitochondrial Metabolic Reprogramming and Inhibits Pulmonary Fibrosis.
Robert N Willette, Parth Mangrolia, Stephen M Pondell, Christopher Young Woo Lee, Sanghee Yoo, Marc S Rudoltz

J Pharmacol Exp Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repression of LKB1 by Sensitizes -Dependent Lymphoma to Biguanide Treatment.
Said Izreig, Alexandra Gariepy, Irem Kaymak, Hannah R Bridges, Ariel O Donayo, Marc S Rudoltz

Cell Rep Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Regard to Brown and Adler.
Marc S Rudoltz

Int J Radiat Oncol Biol Phys· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of yogurt and applesauce on the oral bioavailability of nilotinib in healthy volunteers.
Ophelia Q P Yin, Marc Rudoltz, Ivana Galetic, Jeiry Filian, Arun Krishna

J Clin Pharmacol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
Timothy P Hughes, Andreas Hochhaus, Susan Branford, Martin C Müller, Jaspal S Kaeda, Marc S Rudoltz

Blood· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Jorge E Cortes, Michele Baccarani, François Guilhot, Brian J Druker, Susan Branford, Marc Rudoltz

J Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
Hagop M Kantarjian, Richard A Larson, Francois Guilhot, Stephen G O'Brien, Manisha Mone, Marc Rudoltz

Cancer· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
James A Posey, M Wasif Saif, Ronda Carlisle, Andrew Goetz, Jinee Rizzo, Marc S Rudoltz

Clin Cancer Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis